X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (273) 273
fenretinide (238) 238
oncology (186) 186
female (176) 176
animals (155) 155
index medicus (134) 134
fenretinide - pharmacology (114) 114
apoptosis (110) 110
fenretinide - administration & dosage (108) 108
fenretinide - therapeutic use (96) 96
mice (94) 94
male (92) 92
cancer (76) 76
apoptosis - drug effects (74) 74
middle aged (74) 74
rats (70) 70
antineoplastic agents - pharmacology (69) 69
cell line, tumor (66) 66
retinoids (64) 64
adult (62) 62
breast-cancer (62) 62
n-retinamide (61) 61
chemoprevention (59) 59
prevention (54) 54
tretinoin - analogs & derivatives (52) 52
neuroblastoma (51) 51
pharmacology & pharmacy (51) 51
aged (49) 49
biochemistry & molecular biology (48) 48
retinoic acid (47) 47
antineoplastic agents - administration & dosage (44) 44
antineoplastic agents - therapeutic use (44) 44
dose-response relationship, drug (44) 44
4-hpr (41) 41
neuroblastoma - drug therapy (38) 38
fenretinide - adverse effects (37) 37
tumor cells, cultured (37) 37
vitamin a - blood (37) 37
expression (36) 36
synthetic retinoid fenretinide (35) 35
administration, oral (34) 34
anticarcinogenic agents - therapeutic use (34) 34
breast neoplasms - prevention & control (34) 34
fenretinide - pharmacokinetics (33) 33
article (32) 32
breast cancer (32) 32
induction (32) 32
tretinoin - pharmacology (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
research (31) 31
tamoxifen (31) 31
breast neoplasms - drug therapy (30) 30
metabolism (30) 30
vitamin-a (30) 30
analysis (29) 29
cell biology (28) 28
drug synergism (28) 28
n- retinamide (28) 28
phase-i trial (28) 28
acid (27) 27
cell division - drug effects (27) 27
inhibition (27) 27
treatment outcome (27) 27
cell survival - drug effects (26) 26
tretinoin - administration & dosage (26) 26
pharmacokinetics (25) 25
breast neoplasms - pathology (24) 24
care and treatment (24) 24
tumors (24) 24
differentiation (23) 23
disease models, animal (23) 23
dosage and administration (23) 23
fenretinide - chemistry (23) 23
in-vitro (23) 23
time factors (23) 23
trans-retinoic acid (23) 23
13-cis-retinoic acid (22) 22
cells (22) 22
chemotherapy (22) 22
medicine & public health (22) 22
retinoid (22) 22
gene-expression (21) 21
growth (21) 21
mice, nude (21) 21
physiological aspects (21) 21
rats, sprague-dawley (21) 21
therapy (21) 21
antineoplastic agents - adverse effects (20) 20
drug therapy (20) 20
rat (20) 20
cell line (19) 19
flow cytometry (19) 19
lines (19) 19
neuroblastoma - pathology (19) 19
proteins (19) 19
randomized-trial (19) 19
antineoplastic agents - chemistry (18) 18
carcinogenesis (18) 18
hematology (18) 18
mammary neoplasms, experimental - prevention & control (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 07/2017, Volume 141, Issue 2, pp. 405 - 413
We previously reported that concurrent ketoconazole, an oral anti‐fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid,... 
neuroblastoma | ketoconazole | fenretinide | 4‐oxo‐4‐HPR | 4-oxo-4-HPR | INDUCED CELL-DEATH | INDUCED APOPTOSIS | SYNERGISTIC ACTIVITY | ORGANIZED LIPID COMPLEX | CHILDRENS ONCOLOGY GROUP | LINES | RECURRENT NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYTOTOXICITY | N-(4-HYDROXYPHENYL)RETINAMIDE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Drug Administration Schedule | Ketoconazole - administration & dosage | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Ketoconazole - therapeutic use | Fenretinide - therapeutic use | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Cell Line, Tumor | Fenretinide - administration & dosage | Mice | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Enzyme inhibitors | Neuroblastoma | Metabolites | Ketoconazole | Consulting services | Analysis | Biotechnology | Animal models | Fungicides | Toxicity | Clinical trials | Cytotoxicity | In vitro testing | Assaying | Anticancer properties | Fungi | Xenografts | Children | Medical research | Liquid chromatography | Metabolism | High-performance liquid chromatography | Inhibitors | Cell lines | Antitumor activity | Plasma levels | Plasmas (physics) | Apoptosis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 8, pp. 2216 - 2226
Purpose: Metastatic melanoma is characterized by extremely poor survival rates and hence novel therapies are urgently required. The ability of many anticancer... 
CANCER-CELLS | METASTATIC MELANOMA | PROTEIN | ONCOLOGY | FENRETINIDE-INDUCED APOPTOSIS | ER STRESS | DEATH | BRAF | ENDOPLASMIC-RETICULUM STRESS | BORTEZOMIB | HUMAN GLIOMA-CELLS | Piperazines - administration & dosage | Microtubule-Associated Proteins - genetics | Apoptosis - drug effects | Microtubule-Associated Proteins - metabolism | Humans | Pyrazines - administration & dosage | Endoplasmic Reticulum - metabolism | Autophagy - drug effects | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | RNA Interference | Fenretinide - administration & dosage | Female | Boronic Acids - administration & dosage | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Bortezomib | Fenretinide - pharmacology | Nitrophenols - administration & dosage | Melanoma - pathology | Sulfonamides - pharmacology | Piperazines - pharmacology | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Biphenyl Compounds - administration & dosage | Cell Line, Tumor | Luminescent Proteins - genetics | Mice | Pyrazines - pharmacology | Microscopy, Fluorescence | Sulfonamides - administration & dosage | Boronic Acids - pharmacology | Luminescent Proteins - metabolism
Journal Article
Cancer Research, ISSN 0008-5472, 07/2008, Volume 68, Issue 13, pp. 5363 - 5369
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3749 - 3756
Purpose Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed... 
THERAPY | INHIBITION | N-(4-HYDROXYPHENYL) RETINAMIDE | CLINICAL-TRIAL | ONCOLOGY | BINDING PROTEIN-3 | AROMATASE | PHASE-I | EXPRESSION | SYNTHETIC RETINOID FENRETINIDE | GROWTH-FACTOR-I | Multivariate Analysis | Receptors, Estrogen - metabolism | Humans | Middle Aged | Insulin-Like Growth Factor Binding Protein 3 - blood | Receptor, ErbB-2 - metabolism | Premenopause - blood | Tamoxifen - administration & dosage | Incidence | Receptors, Progesterone - metabolism | Antineoplastic Agents, Hormonal - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Anticarcinogenic Agents - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Carcinoma, Lobular - prevention & control | Fenretinide - administration & dosage | Adult | Female | Anticarcinogenic Agents - adverse effects | Breast Neoplasms - diagnostic imaging | Odds Ratio | Anticarcinogenic Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Proportional Hazards Models | Tamoxifen - blood | Treatment Outcome | Mammography | Anticarcinogenic Agents - blood | Antineoplastic Agents, Hormonal - blood | Breast Neoplasms - prevention & control | Biomarkers, Tumor - blood | Drug Synergism | Fenretinide - blood | Fenretinide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Tamoxifen - adverse effects | Insulin-Like Growth Factor I - metabolism | Vitamin A - blood | Carcinoma, Intraductal, Noninfiltrating - prevention & control | Fenretinide - adverse effects | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4550 - 4555
Journal Article
American Journal of Respiratory Cell and Molecular Biology, ISSN 1044-1549, 06/2010, Volume 42, Issue 6, pp. 716 - 724
Employing genetic mouse models we have recently shown that ceramide accumulation is critically involved in the pathogenesis of cystic fibrosis (CF) lung... 
Infection | Ceramide | Cystic fibrosis | Inflammation | Acid sphingomyelinase | infection | BRONCHIAL EPITHELIAL-CELLS | CHOLESTEROL | acid sphingomyelinase | BIOCHEMISTRY & MOLECULAR BIOLOGY | KAPPA-B | IDENTIFICATION | DEFICIENCY | FENRETINIDE | CELL BIOLOGY | ceramide | inflammation | RESPIRATORY SYSTEM | cystic fibrosis | PSEUDOMONAS-AERUGINOSA | ACCUMULATION | CFTR | Respiratory Mucosa - drug effects | Cystic Fibrosis - enzymology | Humans | Respiratory Tract Infections - enzymology | Respiratory Tract Infections - prevention & control | Pseudomonas Infections - prevention & control | Lung - enzymology | Cystic Fibrosis - immunology | Mass Spectrometry | Respiratory Mucosa - immunology | Sphingomyelin Phosphodiesterase - metabolism | Inflammation Mediators - metabolism | Aging | Pneumonia - immunology | Anti-Inflammatory Agents - administration & dosage | Disease Models, Animal | Mice, Inbred CFTR | Ceramides - metabolism | Cytokines - metabolism | Administration, Oral | Anti-Inflammatory Agents - pharmacology | Diacylglycerol Kinase - metabolism | Pneumonia - enzymology | Respiratory Mucosa - enzymology | Administration, Inhalation | Phosphodiesterase Inhibitors - pharmacology | Treatment Outcome | Cystic Fibrosis - complications | Pseudomonas Infections - immunology | Phosphodiesterase Inhibitors - administration & dosage | Animals | Pneumonia - drug therapy | Sphingomyelin Phosphodiesterase - antagonists & inhibitors | Lung - drug effects | Respiratory Tract Infections - immunology | Pneumonia - complications | Mice | Oligopeptides - administration & dosage | Cystic Fibrosis - drug therapy | Lung - immunology | Microscopy, Fluorescence | Pseudomonas Infections - enzymology
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2011, Volume 17, Issue 21, pp. 6858 - 6866
Journal Article
Cancer Prevention Research, ISSN 1940-6207, 01/2017, Volume 10, Issue 1, pp. 76 - 88
Over one third of patients who have undergone oral squamous cell carcinoma (OSCC) surgical resections develop life-threatening and often untreatable... 
BIOLOGICAL FUNCTIONS | SOLID TUMORS | C-ABL | ONCOLOGY | TYROSINE KINASES | FOCAL ADHESION KINASE | GROWTH-FACTOR | NF-KAPPA-B | PHASE-I | CANCER-THERAPY | SIGNAL TRANSDUCER | Estradiol - analogs & derivatives | Phosphorylation | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Carcinoma, Squamous Cell - pathology | Humans | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - surgery | Male | Receptors, Interleukin-6 - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Anticarcinogenic Agents - administration & dosage | Estradiol - adverse effects | Fenretinide - administration & dosage | Anticarcinogenic Agents - adverse effects | STAT3 Transcription Factor - metabolism | Anticarcinogenic Agents - therapeutic use | Mouth Neoplasms - prevention & control | Tumor Microenvironment - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Estradiol - therapeutic use | Neoplasm Recurrence, Local - prevention & control | Neoplasm Invasiveness | Estradiol - administration & dosage | Carcinoma, Squamous Cell - prevention & control | Carcinogenesis - drug effects | Xenograft Model Antitumor Assays | Fenretinide - therapeutic use | Phenotype | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Differentiation - drug effects | Mice, Nude | Mouth Neoplasms - surgery | Cell Line, Tumor | Mouth Neoplasms - pathology | Mice | Fenretinide - adverse effects | Index Medicus | tocilizumab | oral squamous cell carcinoma | fenretinide | secondary chemoprevention | STAT3 | 2-methoxyestradiol
Journal Article
Journal Article
Journal Article